CTOs on the Move

Porzio Life Sciences

www.porziolifesciences.com

 
Regulatory compliance software solutions, products and services assist pharmaceutical, medical device and biotechnology companies in complying with marketing and sales regulations.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Mental Health Technologies

MHT is a SaaS company focused on testing and measuring Mental Health & Substance Abuse disorders. We aim to improve healthcare for both patients & providers.

Defined Health

Defined Health is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Concerto HealthAI

Concerto HealthAI is a global leader in real-world data, AI technology, and real-world evidence services for precision oncology and dedicated to engineering integrated data and technology solutions that help achieve the best possible outcomes for patients.

Medical Center Compounding

Medical Center Compounding is a Cleveland, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.